Kexing Biopharm Expands Global Reach: Apexelsin® Approved in the Philippines

Recently, Kexing Biopharm announced an important milestone in its overseas commercialization strategy. Its internationally marketed drug—Paclitaxel for Injection (Albumin-bound) (brand name: Apexelsin®)—has officially received marketing approval from the Philippine Food and Drug Administration (FDA).

🌏 Key Product Highlight: Apexelsin®

Compared with conventional paclitaxel injections and liposomal paclitaxel formulations, albumin-bound paclitaxel demonstrates significant clinical advantages, including:

• Improved safety profile

• Better patient compliance

• Strong clinical recognition

• Indispensable value in oncology treatment

These advantages make it an increasingly important option in cancer therapy worldwide.

🇵🇭 Philippine Market Significance

As a major pharmaceutical market in Southeast Asia, the Philippines has experienced rising demand in recent years for high-quality medicines.

The approval of Apexelsin® will now provide local cancer patients with a new and important treatment option, further improving access to advanced oncology therapies.

🌐 Global Expansion Progress

Since obtaining marketing authorization in the European Union in 2024, Apexelsin® has been accelerating its global rollout. Over the past two years, it has received approvals in multiple countries and regions, including:

• United Kingdom

• Peru

• Uruguay

• Argentina

• Oman

• Malaysia

• Macao, China

These approvals have helped establish a broad global sales network spanning:

👉 Europe
👉 Latin America
👉 Southeast Asia
👉 Middle East

🚀 Outlook

Looking ahead, Kexing Biopharm will continue working with global partners to further improve access to high-quality medicines and expand the availability of advanced treatment options worldwide.

https://www.kexingbiopharm.com/
Kexing Biopharm